Dr. Sven Kili contributes extensive expertise in cellular and genetic therapeutics to the Cell One Partners team. As the Head of Development for the Cell and Gene Therapy division of GSK Rare Diseases, he oversaw teams developing and commercializing gene therapies for various rare genetic disorders, including Strimvelis®, the first ex-vivo gene therapy approved for children with ADA-SCID. His leadership extended to therapies for Wiskott-Aldrich syndrome (WAS), Metachromatic Leukodystrophy (MLD), and Beta-Thalassemia. At Sanofi (Genzyme) Biosurgery, Dr. Kili served as Senior Director of Cell Therapy and Regenerative Medicine, where he led the clinical development, approval, and commercialization of the first combined ATMP product in the EU, MACI®. He also prepared and submitted advanced therapy regulatory filings for Australia and the US, including health technology assessments, and managed late-stage developments for Carticel® and Epicel® in the US.

​

Dr. Kili's extensive regulatory and operational expertise is further highlighted by his role at Geistlich Pharma, where he led cell therapy activities and oversaw all UK and Irish regulatory functions, serving as the QPPV for pharmacovigilance. He is an active board member of CCRM, co-chair of the ARM Gene Therapy Steering Committee, and co-chair of the ISCT Business Models & Investment Committee. Additionally, he serves on the SAB for the LGC Group and holds an academic appointment as Chair at UCL for the MSc in Manufacture and Commercialization of Stem Cell and Gene Therapies, where he leads the course steering committee. Dr. Kili's comprehensive experience in developing and commercializing advanced therapies, combined with his regulatory acumen, makes him a significant contributor to the field.